DongKookPharmaceuticalCo.,Ltd. Logo

DongKookPharmaceuticalCo.,Ltd.

Develops, manufactures, and distributes pharmaceuticals and healthcare products globally.

086450 | KO

Overview

Corporate Details

ISIN(s):
KR7086450004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로 715 동국제약 청담빌딩, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1968, Dongkook Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacture, and distribution of pharmaceuticals, medical devices, and healthcare products. With a core philosophy centered on improving human life, the company focuses on human-oriented R&D and operates its own Active Pharmaceutical Ingredient (API) synthesis facilities. Its diverse portfolio includes prescription and non-prescription drugs, generic medications, and specialized therapeutic products such as anesthetics, contrast media, and anti-cancer agents. The company also produces well-known consumer brands like Madecassol and Oramedy, serving both domestic and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.9 MB
2025-08-12 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.3 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 413.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 3.0 MB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.0 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 24.6 KB
2025-03-13 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 666.2 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.1 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 187.3 KB
2025-02-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 9.9 KB
2025-02-06 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 11.2 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-12-13 00:00
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.7 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.6 MB
2024-10-15 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 33.7 KB

Automate Your Workflow. Get a real-time feed of all DongKookPharmaceuticalCo.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKookPharmaceuticalCo.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKookPharmaceuticalCo.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO
Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN

Talk to a Data Expert

Have a question? We'll get back to you promptly.